Table 2. Adverse Events Summary for Vistusertib Plus Anastrozole Arm vs Anastrozole Alone Arm for Treatment of Endometrial Cancer.

Incidence and type of adverse event	No. (%)
	Vistusertib + anastrozole (n = 49)		Anastrozole (n = 24)
	Any grade	Grade 3 or 4	Any grade	Grade 3 or 4
Nausea	25 (51)	1 (2)	2 (8)	0
Fatigue	34 (69)	4 (8)	7 (29)	0
Vomiting	11 (22)	1 (2)	1 (4)	0
Diarrhea	20 (41)	1 (2)	3 (13)	0
Arthralgia	11 (22)	0	7 (29)	0
Decrease in lymphocytes count	17 (35)	10 (20)	3 (13)	2 (8)
Hyperglycemia	15 (31)	6 (12)	2 (8)	0
Anemia	13 (27)	2 (4)	1 (4)	0
≥1 SAE	20 (41)	NA	3 (13)	NA
≥1 Vistusertib-related SAE	11 (22)	NA	NA	NA

Abbreviations: NA, not applicable; SAE, serious adverse event.